Drugs by condition
Drugs approved for primary biliary cholangitis
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
3
Still marketed, NDA or BLA
Drug classes
3
Novel drugs
3
New molecular entities and new biologics
In development
3
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for primary biliary cholangitis.
All approved drugs for primary biliary cholangitis, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 4 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Drugs in development for primary biliary cholangitis
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- Saroglitazar MagnesiumPhase 35 trials
Zydus Therapeutics Inc. · Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Fibrosis
- VolixibatSHP626Phase 22 trials
Mirum Pharmaceuticals, Inc. · Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, PBC
- CNP-104Phase 21 trial
COUR Pharmaceutical Development Company, Inc. · Primary Biliary Cholangitis
1 discontinued brand-name drugs whose label still names it
- Urso 250 Ursodiol
More on primary biliary cholangitis: recruiting trials · published research
Related in gastroenterology and liver: MASH (fatty liver disease) · Acid reflux (GERD) · Irritable bowel syndrome · Chronic constipation · Nausea and vomiting · Eosinophilic esophagitis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.